Biotech Bid Up Following First Patient Dosage
12 January 2023 - 1:25AM
AllPennyStocks.com
A Boston-based biotech company is turning
heads on Wednesday after the company announced that the first
patient was dosed in its Phase 1/2a monotherapy clinical trial of
ATRN-119,...
To read the full story on AllPennyStocks.com, click
here.
Aprea Therapeutics (NASDAQ:APRE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aprea Therapeutics (NASDAQ:APRE)
Historical Stock Chart
From Apr 2023 to Apr 2024